Literature DB >> 9543068

B cell lymphoma-associated hemophagocytic syndrome after PBSCT.

T Takahashi1, Y Kanda, M Mori, T Saito, S Chiba, K Mitani, H Hirai, Y Yazaki.   

Abstract

Hemophagocytic syndrome (HPS) associated with T cell lymphoma is well known, but an association with B cell lymphoma is rare. We report a patient who developed subcutaneous non-Hodgkin's lymphoma (NHL) of B cell origin. Autologous peripheral blood stem cell transplantation (PBSCT) was undertaken in her second complete remission (CR), but HPS appeared 5 months after transplantation. The patient deteriorated rapidly and died of metabolic acidosis. Necropsy revealed that she had relapsed B cell NHL involving liver, spleen and bone marrow. B cell NHL after PBSCT, associated with HPS as an initial sign, is rare. We report this case and review the literature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543068     DOI: 10.1038/sj.bmt.1701143

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation.

Authors:  K Fukuno; H Tsurumi; T Yamada; M Oyama; H Moriwaki
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas.

Authors:  Tatsuharu Ohno; Yasunori Ueda; Ken-ichi Nagai; Takayuki Takahashi; Yoshiteru Konaka; Teruyuki Takamatsu; Takayo Suzuki; Masataka Sasada; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

3.  Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT.

Authors:  R Kobayashi; J Tanaka; S Hashino; S Ota; Y Torimoto; Y Kakinoki; S Yamamoto; M Kurosawa; N Hatakeyama; Y Haseyama; H Sakai; K Sato; T Fukuhara
Journal:  Bone Marrow Transplant       Date:  2013-09-16       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.